September is STXBP1 disorders awareness month, an initiative aimed at raising awareness of STXBP1-related rare genetic disorders, such as epileptic encephalopathy. Although STXBP1-related disorders are rare; STXBP1 is the 5th most common cause of genetic forms of epilepsy1. This raises the possibility to test both gene-targeting treatments and general anti-epileptic therapies in STXBP1 models. As seen below, the effect of such targeted treatments can be studied using the Stxbp1 +/- mouse model with robust and reproducible epileptic-like phenotypes.
To help you fine-tune your lead compound’s bioavailability, InnoSer has ample experience in carrying out PK/PD studies and analyses. To ensure your compound’s safety, InnoSer can additionally perform safety pharmacology analyses.
Be the first to know – get this news straight to your inbox
InnoSer provides a variety of validated in vitro and in vivo screening tests for psychiatry and neurology. If you require additional information, feel free to reach out, and we will respond within a few days.
We provide a monthly update from our neurology labs containing scientific insights into our research services. To get news straight to your inbox please sign up here.